News

Applications are open for the MedTech Innovator Competition 2021 »

MedTech Innovator is the largest accelerator of medical devices in the world. We provide an unparalleled platform to support startups with the access, visibility, and network to bring their innovations to patients. Our alumni have raised over $2B in follow-on funding, brought 75 products to the market, and achieved 11 acquisitions. In its latest CipherBio report, Silicon Valley Bank recognized MTI as having the most active fundraising portfolio in 2020 of any accelerator.

Applications are open for the 2021 program. This is a highly selective and unique opportunity for startups and scale-ups to be showcased and gain access to healthcare stakeholders including investors, customers, and industry leaders such as Johnson & Johnson, Baxter, Olympus, W. L. Gore, Nipro, Edwards Lifesciences, Dexcom, Asahi Intecc, Fujikura, Jabil Healthcare, Maxim Integrated Products, and others. This year, up to $500,000 in non-dilutive prizes will be awarded.

Showcase at Leading Industry Conferences

Among other benefits, companies selected for the 2021 program will receive showcase presentation slots and one complimentary registration to the MedTech Innovator Summit and WSGR Medical Device Conference in June as well as The MedTech Conference powered by AdvaMed in September.

Prizes

Compete for up to $500,000 in non-dilutive cash prizes and in-kind awards

Who Should Apply?

All early to mid-stage medical device, diagnostic, or digital health companies are encouraged to apply. Preference for the Accelerator program will be given to companies that have not yet raised a Series B. All companies are eligible for the Showcase program.

Companies do not need to relocate to participate. MedTech Innovator does not charge or take equity for participation, and there is no application fee.

Apply Now

Recent News

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.

04/02/2026

ATCC Receives New CDC Award to Help Fast-track Diagnostic Tests for Future Disease Outbreaks

TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated,